Wide Ranks

CARM

Carisma Therapeutics, Inc.

0.8410

Top Statistics
Market Cap 35 M Forward PE -1.09 Revenue Growth -11.60 %
Current Ratio 3.23 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.1630 Enterprise / Revenue 0.5080 Price To Sales Trailing12 Months 1.73
Profitability
Profit Margins 0.00 % Operating Margins -388.30 %
Balance Sheet
Total Cash 28 M Total Cash Per Share 0.6740 Total Debt 3 M
Total Debt To Equity Current Ratio 3.23 Book Value Per Share -0.2660
All Measures
Short Ratio 311.00 % Message Board Id finmb_433272951 Shares Short Prior Month 1 M
Return On Equity -3.63 City Philadelphia Uuid dbc3c499-e939-3e2f-95bc-27e9130b1e93
Previous Close 0.8500 First Trade Date Epoch Utc 1 B Book Value -0.2660
Total Debt 3 M Volume 122911 Last Split Date 1 B
Fifty Two Week Low 0.8000 Total Cash Per Share 0.6740 Total Revenue 20 M
Shares Short Previous Month Date 1 B Target Median Price 6.00 Audit Risk 8
Max Age 86400 Recommendation Mean 1.20 Sand P52 Week Change 0.3133
Operating Margins -388.30 % Last Dividend Value 0.3610 Target Mean Price 9.80
Net Income To Common -63800000 Short Percent Of Float 0.0167 Implied Shares Outstanding 41 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 153130
Average Volume10days 153130 Total Cash 28 M Next Fiscal Year End 1 B
Revenue Per Share 0.4930 Held Percent Insiders 0.2853 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 7
Regular Market Previous Close 0.8500 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.9595 Open 0.8500 Free Cashflow -41385752
State PA Dividend Yield 0.00 % Return On Assets -0.5608
Time Zone Short Name EST Board Risk 7 Trailing Eps -1.52
Day Low 0.8401 Address1 3675 Market Street Shares Outstanding 41 M
Compensation Risk 8 Price Hint 4 Target High Price 24.00
Website https://www.carismatx.com 52 Week Change -0.6496 Average Volume 147076
Forward Eps -0.9100 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 266.40 % Last Split Factor 1:20 Regular Market Day High 0.8722
Is_sp_500 False Profit Margins 0.00 % Fifty Two Week High 3.16
Day High 0.8722 Shares Short 558578 Regular Market Open 0.8500
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 0.5080
Revenue Growth -11.60 % Shares Percent Shares Out 0.0134 Operating Cashflow -67662000
Currency USD Time Zone Full Name America/New_York Market Cap 35 M
Is_nasdaq_100 False Zip 19104 Quote Type EQUITY
Industry Biotechnology Long Name Carisma Therapeutics, Inc. Overall Risk 8
Regular Market Day Low 0.8401 Held Percent Institutions 0.3151 Current Price 0.8410
Address2 Suite 200 Enterprise To Ebitda -0.1630 Financial Currency USD
Current Ratio 3.23 Gross Margins -213.35 % Industry Disp Biotechnology
Number Of Analyst Opinions 5 Country United States Float Shares 22 M
Two Hundred Day Average 1.39 Governance Epoch Date 1 B Enterprise Value 10 M
Price To Sales Trailing12 Months 1.73 Forward PE -1.09 Regular Market Volume 122911
Last Dividend Date 1 B Ebitda -63367000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States.

The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.

It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases.

The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.

The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.